It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The transition from naive to primed pluripotency is accompanied by an extensive reorganisation of transcriptional and epigenetic programmes. However, the role of transcriptional enhancers and three-dimensional chromatin organisation in coordinating these developmental programmes remains incompletely understood. Here, we generate a high-resolution atlas of gene regulatory interactions, chromatin profiles and transcription factor occupancy in naive and primed human pluripotent stem cells, and develop a network-graph approach to examine the atlas at multiple spatial scales. We uncover highly connected promoter hubs that change substantially in interaction frequency and in transcriptional co-regulation between pluripotent states. Small hubs frequently merge to form larger networks in primed cells, often linked by newly-formed Polycomb-associated interactions. We identify widespread state-specific differences in enhancer activity and interactivity that correspond with an extensive reconfiguration of OCT4, SOX2 and NANOG binding and target gene expression. These findings provide multilayered insights into the chromatin-based gene regulatory control of human pluripotent states.
The role of transcriptional enhancers and 3D chromatin organisation in coordinating the transition from naive to primed pluripotency remains poorly understood. Here the authors generate a high-resolution atlas of gene regulatory interactions, chromatin profiles and transcription factor occupancy in naive and primed human pluripotent stem cells to provide insights into these developmental processes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Babraham Institute, Lymphocyte Signalling and Development Programme, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777); Babraham Institute, Nuclear Dynamics Programme, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777)
2 Babraham Institute, Epigenetics Programme, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777)
3 Babraham Institute, Nuclear Dynamics Programme, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777); University of Birmingham, Centre for Computational Biology, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486)
4 Babraham Institute, Nuclear Dynamics Programme, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777); Babraham Institute, Epigenetics Programme, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777)
5 Babraham Institute, Epigenetics Programme, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777); Wellcome – MRC Cambridge Stem Cell Institute, Cambridge, UK (GRID:grid.449973.4) (ISNI:0000 0004 0612 0791)